Dihexa vs Humanin
Both Dihexa and Humanin are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
Dihexa
Evidence CDihexa (PNB-0408)
An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.
View full Dihexa profile →Humanin
Evidence BHumanin (HN)
A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.
View full Humanin profile →Side-by-Side
| Attribute | Dihexa | Humanin |
|---|---|---|
| Evidence Grade | C | B |
| FDA Status | Not FDA-approved — research compound (HGF/c-Met-mimetic) | Not FDA-approved — mitochondrial-derived peptide research compound |
| Typical Dose | 8–45 mg orally daily (research-only) | Research range: 0.5–1 mg subcutaneous (rare clinical use) |
| Clinics Indexed | 10 | 5 |
| Categories | cognitive, neuroprotection | mitochondrial, longevity, neuroprotection |
Key reported benefits — Dihexa
- ✓Synaptogenesis (preclinical)
- ✓Memory improvement (animal)
- ✓Possible Alzheimer's relevance
Key reported benefits — Humanin
- ✓Cytoprotection
- ✓Anti-amyloid effects
- ✓Insulin sensitization
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.